JNJ-64619178

JNJ-64619178 is a **selective and potent inhibitor of protein arginine methyltransferase 5 (PRMT5)**, developed primarily for the treatment of advanced solid tumors and non-Hodgkin lymphoma. PRMT5 is an epigenetic regulator involved in methylation of arginine residues on histones and non-histone proteins, and its inhibition leads to impaired DNA damage response, reduced expression of repair proteins, and antitumor activity. JNJ-64619178 has demonstrated manageable dose-dependent toxicity and early evidence of antitumor activity, with highest activity noted in adenoid cystic carcinoma. It has also shown potential as a radiosensitizer in prostate cancer by suppressing double-strand break repair and neuroendocrine differentiation induced by fractionated irradiation[1][3][5].

Other names

JNJ-64619178JNJ64619178JNJ 64619178